A novel Y319H substitution in CYP51C associated with azole resistance in Aspergillus flavus

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6615-6619

  Paul, R A ^a   Rudramurthy, S M ^a   Meis, J F ^b,c   Mouton, J W ^b,c   Chakrabarti, A ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE C; UNCLASSIFIED DRUG; VORICONAZOLE; FUNGAL PROTEIN; PYRROLE DERIVATIVE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FLAVUS; GENE MUTATION; MINIMUM EFFECTIVE CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; DRUG EFFECTS; GENETICS; MOLECULAR GENETICS; MUTATION;

ASPERGILLUS FLAVUS; AZOLES; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; VORICONAZOLE;

EID: 84942900657     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00637-15     Document Type: Article

References (28)

1. Pasqualotto AC. 2009. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 47(Suppl 1):S261-S270.
2. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. 2007. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153:1677-1692. http://dx.doi.org/10.1099/mic.0.2007/007641-0.
3. Krishnan S, Manavathu EK, Chandrasekar PH. 2009. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses 52:206-222. http://dx.doi.org/10.1111/j.1439-0507.2008.01642.x.
4. Chakrabarti A, Shivaprakash MR, Singh R, Tarai B, George VK, Fomda BA, Gupta A. 2008. Fungal endophthalmitis: fourteen years' experience from a center in India. Retina 28:1400-1407. http://dx.doi.org/10.1097/IAE.0b013e318185e943.
5. Chakrabarti A, Rudramurthy SM, Panda N, Das A, Singh A. 2015. Epidemiology of chronic fungal rhinosinusitis in rural India. Mycoses 58:294-302. http://dx.doi.org/10.1111/myc.12314.
6. Chakrabarti A, Singh R. 2011. The emerging epidemiology of mould infections in developing countries. Curr Opin Infect Dis 24:521-526. http://dx.doi.org/10.1097/QCO.0b013e32834ab21e.
7. Khan ZU, Sanyal SC, Mokaddas E, Vislocky I, Anim JT, Salama AL, Shuhaiber H. 1997. Endocarditis due to Aspergillus flavus. Mycoses 40: 213-217. http://dx.doi.org/10.1111/j.1439-0507.1997.tb00217.x.
8. Khan ZU, Ahmad S, Mokaddas E, Said T, Nair MP, Halim MA, Nampoory MR, McGinnis MR. 2007. Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1→3)-beta-D-glucan in clinical specimens. J Med Microbiol 56:129-132. http://dx.doi.org/10.1099/jmm.0.46549-0.
9. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 9:789-795. http://dx.doi.org/10.1016/S1473-3099(09)70265-8.
10. Chowdhary A, Kathuria S, Xu J, Meis JF. 2013. Emergence of azoleresistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 9:e1003633. http://dx.doi.org/10.1371/journal.ppat.1003633.
11. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67:362-366. http://dx.doi.org/10.1093/jac/dkr443.
12. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15:1068-1076. http://dx.doi.org/10.3201/eid1507.090043.
13. Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK. 2008. Molecular characterisation of CYP51A and CYP51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents 32:519-524. http://dx.doi.org/10.1016/j.ijantimicag.2008.06.018.
14. Natesan SK, Lamichchane AK, Swaminathan S, Wu W. 2013. Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus. Diagn Microbiol Infect Dis 76:458-463. http://dx.doi.org/10.1016/j.diagmicrobio.2013.04.022.
15. Liu W, Sun Y, Chen W, Liu W, Wan Z, Bu D, Li R. 2012. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother 56:2598-2603. http://dx.doi.org/10.1128/AAC.05477-11.
16. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol 49:586-590. http://dx.doi.org/10.1128/JCM.02136-10.
17. Glass NL, Donaldson GC. 1995. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. Appl Environ Microbiol 61:1323-1330.
18. Geiser DM, Pitt JI, Taylor JW. 1998. Cryptic speciation and recombination in the aflatoxin-producing fungus Aspergillus flavus. Proc Natl Acad Sci U S A 95:388-393. http://dx.doi.org/10.1073/pnas.95.1.388.
19. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard; 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
20. EUCAST. 2008. EUCAST definitive document E.DEF 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/4ESCMID-Library/3Publications/EUCAST-Documents/Other-Documents/EUCAST-moulds-DEFINITIVE-document-V-ISO-April-08%20final.pdf.
21. Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF. 2011. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 54:e583-e589. http://dx.doi.org/10.1111/j.1439-0507.2010.01996.x.
22. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. 2011. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis 71:370-377. http://dx.doi.org/10.1016/j.diagmicrobio.2011.08.006.
23. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. 2010. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. BMC Bioinformatics 11:548.
24. Williams LE, Wernegreen JJ. 2013. Sequence context of indel mutations and their effect on protein evolution in a bacterial endosymbiont. Genome Biol Evol 5:599-605. http://dx.doi.org/10.1093/gbe/evt033.
25. Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G, Verweij PE, Melchers WJ. 2011. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol 48:1062-1070. http://dx.doi.org/10.1016/j.fgb.2011.08.002.
26. Wang J, Ma C, Fiorin G, Carnevale V, Wang T, Hu F, Lamb RA, Pinto LH, Hong M, Klein ML, DeGrado WF. 2011. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J Am Chem Soc 133:12834-12841. http://dx.doi.org/10.1021/ja204969m.
27. Kumar A, Purohit R. 2014. Use of long term molecular dynamics simulation in predicting cancer associated SNPs. PLoS Comput Biol 10: e1003318. http://dx.doi.org/10.1371/journal.pcbi.1003318.
28. Natarajan K, Senapati S. 2012. Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations. PLoS One 7:e42351. http://dx.doi.org/10.1371/journal.pone.0042351.